Zai Lab (09688) rose more than 4%, and as of the latest update, the stock was up 3.84% to HK$18.1, with a turnover of HK$82.7149 million. On April 15, Zai Lab announced a clinical collaboration with Boehringer Ingelheim to develop an innovative combination therapy targeting DLL3. The Ib/II phase study will evaluate the safety, tolerability, and preliminary clinical activity of Zai Lab’s DLL3-targeting ADC zocilurtatug pelitecan (zoci, formerly ZL-1310) in combination with Boehringer Ingelheim’s DLL3/CD3 T-cell engager obrixtamig. Zocilurtatug pelitecan (zoci) is a DLL3-targeting ADC developed by Zai Lab, designed to deliver a potent cytotoxic payload to DLL3-positive tumor cells for the treatment of extensive-stage small cell lung cancer (ES-SCLC). Recent global Phase I results showed that zoci demonstrated potent and durable responses in previously treated ES-SCLC patients, including those with brain metastases, along with a favorable safety profile. Based on these findings, the program has advanced into a global Phase III registrational study.